BR112014029439A2 - derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos - Google Patents
derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmosInfo
- Publication number
- BR112014029439A2 BR112014029439A2 BR112014029439A BR112014029439A BR112014029439A2 BR 112014029439 A2 BR112014029439 A2 BR 112014029439A2 BR 112014029439 A BR112014029439 A BR 112014029439A BR 112014029439 A BR112014029439 A BR 112014029439A BR 112014029439 A2 BR112014029439 A2 BR 112014029439A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- composition
- acid derivatives
- salicylic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 title abstract 3
- 150000003872 salicylic acid derivatives Chemical class 0.000 title abstract 3
- 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101100366888 Dictyostelium discoideum dstA gene Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651757P | 2012-05-25 | 2012-05-25 | |
| PCT/US2013/042689 WO2013177534A2 (en) | 2012-05-25 | 2013-05-24 | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014029439A2 true BR112014029439A2 (pt) | 2017-06-27 |
Family
ID=49624538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014029439A BR112014029439A2 (pt) | 2012-05-25 | 2013-05-24 | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9650399B2 (https=) |
| EP (1) | EP2854819B1 (https=) |
| JP (2) | JP6290871B2 (https=) |
| CN (2) | CN105120854B (https=) |
| BR (1) | BR112014029439A2 (https=) |
| CA (1) | CA2874057A1 (https=) |
| HK (1) | HK1218709A1 (https=) |
| RU (1) | RU2641903C2 (https=) |
| WO (1) | WO2013177534A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2975936A4 (en) * | 2013-03-22 | 2017-03-15 | University of Hawaii | Novel stat3 inhibitors |
| WO2015179956A1 (en) * | 2014-05-30 | 2015-12-03 | The Governing Council Of The University Of Toronto | Sulfonamide compounds and their use as stat5 inhibitors |
| EP3570836A4 (en) * | 2017-01-23 | 2020-08-19 | The University of Hawaii | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE STAT3 INHIBITORS |
| WO2020124262A1 (en) * | 2018-12-21 | 2020-06-25 | The Governing Council Of The University Of Toronto | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| TWI875749B (zh) | 2019-04-05 | 2025-03-11 | 美商凱麥拉醫療公司 | Stat降解劑及其用途 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| CN115551490A (zh) * | 2020-03-05 | 2022-12-30 | 詹皮克斯有限公司 | α取代的STAT抑制剂及其组合物 |
| AU2021232072A1 (en) * | 2020-03-05 | 2022-10-20 | Centessa Pharmaceuticals (Uk) Limited | STAT inhibitory compounds and compositions |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN112941036B (zh) * | 2021-02-08 | 2023-06-09 | 吉林惠康生物药业有限公司 | 一种提高狂犬病毒在人二倍体细胞中复制水平的方法 |
| CN114751927B (zh) * | 2022-03-08 | 2023-10-31 | 中山大学 | 一种硼酸化合物、制备方法及用途 |
| CN118994047B (zh) * | 2024-08-13 | 2026-02-10 | 中国药科大学 | 一种水杨醛衍生物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1701941E (pt) * | 2003-12-11 | 2012-08-03 | Univ Texas | Compostos para o tratamento de doenças proliferativas celulares |
| BRPI0709916B8 (pt) * | 2006-03-31 | 2021-05-25 | Univ Texas | drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas |
| US7960434B2 (en) | 2006-05-19 | 2011-06-14 | University Of South Florida | Small molecule inhibitors of STAT3 with anti-tumor activity |
| UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| CN102099352B (zh) * | 2008-07-10 | 2014-02-26 | 一般社团法人创药分子Ip | 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂 |
| US8586749B2 (en) | 2009-04-06 | 2013-11-19 | University Of Central Florida Research Foundation, Inc. | Compounds that suppress cancer cells and exhibit antitumor activity |
| CN103608010A (zh) * | 2010-08-02 | 2014-02-26 | 中央佛罗里达大学研究基金公司 | 作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物 |
| EP2975936A4 (en) * | 2013-03-22 | 2017-03-15 | University of Hawaii | Novel stat3 inhibitors |
-
2013
- 2013-05-24 CA CA2874057A patent/CA2874057A1/en not_active Abandoned
- 2013-05-24 JP JP2015514226A patent/JP6290871B2/ja not_active Expired - Fee Related
- 2013-05-24 US US14/550,293 patent/US9650399B2/en not_active Expired - Fee Related
- 2013-05-24 CN CN201380038486.1A patent/CN105120854B/zh not_active Expired - Fee Related
- 2013-05-24 RU RU2014152697A patent/RU2641903C2/ru not_active IP Right Cessation
- 2013-05-24 EP EP13794722.2A patent/EP2854819B1/en active Active
- 2013-05-24 HK HK16106053.3A patent/HK1218709A1/zh unknown
- 2013-05-24 WO PCT/US2013/042689 patent/WO2013177534A2/en not_active Ceased
- 2013-05-24 BR BR112014029439A patent/BR112014029439A2/pt not_active Application Discontinuation
- 2013-05-24 CN CN201910222566.1A patent/CN110003104A/zh active Pending
-
2017
- 2017-03-30 US US15/475,108 patent/US10377780B2/en active Active
-
2018
- 2018-02-08 JP JP2018021248A patent/JP6543366B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-25 US US16/451,883 patent/US20190382422A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015522551A (ja) | 2015-08-06 |
| CN105120854A (zh) | 2015-12-02 |
| JP6543366B2 (ja) | 2019-07-10 |
| US20190382422A1 (en) | 2019-12-19 |
| EP2854819A2 (en) | 2015-04-08 |
| JP6290871B2 (ja) | 2018-03-07 |
| US9650399B2 (en) | 2017-05-16 |
| RU2641903C2 (ru) | 2018-01-23 |
| US20150158894A1 (en) | 2015-06-11 |
| WO2013177534A2 (en) | 2013-11-28 |
| US20170267704A1 (en) | 2017-09-21 |
| HK1218709A1 (zh) | 2017-03-10 |
| RU2014152697A (ru) | 2016-07-20 |
| CA2874057A1 (en) | 2013-11-28 |
| JP2018109017A (ja) | 2018-07-12 |
| CN105120854B (zh) | 2019-04-09 |
| EP2854819B1 (en) | 2020-01-15 |
| US10377780B2 (en) | 2019-08-13 |
| EP2854819A4 (en) | 2016-06-15 |
| CN110003104A (zh) | 2019-07-12 |
| WO2013177534A3 (en) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112014010206B8 (pt) | composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto | |
| BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
| BR112015008447A2 (pt) | métodos para tratar câncer | |
| EA201491824A1 (ru) | Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1 | |
| BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| BR112015008480A2 (pt) | compostos de benzeno substituído | |
| BR112013020996A8 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| BR112013026834A2 (pt) | composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio | |
| BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
| BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112014010183B8 (pt) | Composto, composição farmacêutica, produto, e, uso de um composto | |
| NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
| BR112014029706A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| BR112014010576B8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
| TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |